Advertisement
Research Article| Volume 17, ISSUE 4, P721-728, July 1995

Download started.

Ok

Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Patients with chronic active hepatitis C show low lipoprotein(a) (Lp[a]) values. We studied the changes in Lp(a) levels caused by treatment with interferon in 24 patients (9 men and 15 women; mean age, 56.8 ± 7.3 years) affected by chronic active hepatitis C. Fifteen healthy subjects (6 men and 9 women; mean age, 57.4 ± 10.3 years) were used as controls. All of the patients with chronic hepatitis C were treated with intramuscular interferon, 3 million units 3 times per week for 6 months. These patients had lower baseline serum Lp(a) concentrations than the controls (4.8 ± 3.8 mg/dL vs 13.4 ± 10.3 mg/dL, respectively; P = 0.0007). A significant increase in Lp(a) levels (6.6 ± 7.2 mg/dL; P = 0.05) occurred after 6 months of treatment in patients with chronic active hepatitis C. Only complete responders presented a significant increase in Lp(a) values (P = 0.01). We believe that increased Lp(a) levels represent an expression of improved liver functions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoofnagle JH
        Treatment of chronic non-A, non-B hepatitis with recombinant human alpha-IFN: A preliminary report.
        NEJM. 1986; 315: 1575-1578
        • Isaacs A
        • Lindenmann J
        Virus interference. The Interferon.
        Proc R Soc London B Biol Sci. 1957; 147: 258-267
        • Moormier J
        • Retain MJ
        • Westbrook CA
        • et al.
        Low dose interferon in the treatment of hairy cell leukemia.
        J Natl Cancer Inst. 1989; 81: 1172-1179
        • Vance JC
        Interferons: Therapeutic potential in cutaneous diseases.
        Adv Dermatol. 1991; 6: 3-34
        • Rosemberg SA
        • Lotze MT
        • Yang JC
        • et al.
        Combination therapy with interleukin 2 and alpha interferon for the treatment of patients with advanced cancer.
        J Clin Oncol. 1989; 7: 1863-1869
        • Sen GC
        • Ransohoff RM
        Interferon-induced antiviral actions and their regulation.
        Adv Virus Res. 1993; 42: 57-61
        • Fish EN
        • Banerjee K
        • Stebbing N
        Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells.
        Biochem Res Commun. 1983; 112: 537-541
        • Vankelecom H
        • Carmeliet P
        • Heremans H
        • et al.
        Interferon-γ inhibits stimulated adrenocorticotropin, prolactin and growth hormone secretion in normal rat anterior pituitary cell cultures.
        Endocrinology. 1990; 126: 2919-2927
        • Spath-Schwable E
        • Porzsolt F
        • Digel W
        • et al.
        Elevated plasma cortisol levels during interferon-γ treatment.
        Immunopharmacology. 1989; 17: 141-148
        • Memon RA
        • Feingold KR
        • Moser AH
        • et al.
        In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis.
        Endocrinology. 1992; 131: 1695-1702
        • Beutler BA
        • Cerami A
        Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3t3-L1 cells.
        J Immunol. 1986; 135: 3969-3971
        • Berg K
        A new serum type system in man The Lp(a) system.
        Acta Pathol Microbiol Immunol Scand. 1963; 59: 369-382
        • Mbewn AD
        • Durrington PN
        Lipoprotein (a): Structure, properties and possible involvement in thrombogenesis and atherogenesis.
        Atherosclerosis. 1990; 85: 1-14
        • Murai A
        • Miyahara T
        • Fujimoto N
        • et al.
        Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.
        Atherosclerosis. 1986; 59: 199-204
        • Giugno I
        • Ruello P
        • Trovato BA
        • et al.
        Lp(a) in subjects with active chronic hepatitis.
        Atherosclerosis. 1994; 110 (Abstract): S101
        • Dahlen G
        • Berk K
        • Gillnas T
        • Ericson C
        Lp(a) lipoprotein, pre-beta1 lipoprotein in Swedish middle aged males and in patients with coronary heart disease.
        Clin Genet. 1975; 7: 334-341
        • Koltringer P
        • Jurgens G
        A dominant role of lipoprotein (a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis.
        Atherosclerosis. 1985; 58: 187-198
        • Ezratty AM
        • Loscalzo J
        Lipoprotein (a): A risk factor with novel mechanism for the development of atherothrombotic disease.
        in: Mazzaferri EJ Bav RS Kreisberg RA Advances in Endocrinology and Metabolism. 3. Mosby Yearbook, Chicago1992: 237-257
        • Highuchi K
        • Hospettankar AV
        • Law SV
        • et al.
        Human apolipoprotein B (apo B) mRNA: Identification of two distinct apo (B) mRNAs, an mRNA with the apo B-100 sequence and an apo B mRNA containing a premature in-frame translational stop codon, in both liver and intestine.
        Proc Natl Acad Sci USA. 1988; 85: 1772-1776
        • Hixon JE
        • Britten ML
        • Marris JS
        Rainwater DJ. Apolipoprotein (a) [apo (a)] glycoprotein isoforms result from size differences in apo (a) mRNA in baboons.
        J Biol Chem. 1989; 264: 6013-6016
        • Kraft HG
        • Hoppchler F
        Changes of genetic apolipoprotein phenotypes caused by liver transplantation: Implications for apolipoprotein synthesis.
        J Clin Invest. 1989; 83: 137-142
        • McLean JW
        • Tomlinson JE
        • Kuang WJ
        • et al.
        cDNA sequence of human apolipoprotein (a) is homologous to plasminogen.
        Nature. 1987; 330: 132-137
        • Tomlinson JE
        • McLean JW
        • Lawn RM
        Rhesus monkey apoprotein (a). Sequence, evolution and sites of synthesis.
        J Biol Chem. 1989; 264: 5957-5965
        • Krempler F
        • Kostner GM
        • Bolzano K
        • Sandhofer F
        Turnover of lipoprotein (a) in man.
        J Clin Invest. 1980; 65: 1483-1490
        • Krempler F
        • Kostner GM
        • Bolzano K
        • Sandhofer F
        Studies on the metabolism of the lipoprotein Lp(a) in man.
        Atherosclerosis. 1978; 30: 57-65
        • Feely J
        • Barry M
        • Keeling PWN
        • et al.
        Lipoprotein (a) in cirrhosis.
        BMJ. 1992; 304: 545-546
        • Giugno I
        • Ruello P
        • Trovato BA
        • et al.
        Prognostic value of Lp(a) in cirrhosis of the liver.
        Atherosclerosis. 1994; 110 (Abstract): S101
        • Rhoads GG
        • Dahlen G
        • Berg K
        • et al.
        Lp(a) lipoprotein as a risk factor for myocardial infarction.
        JAMA. 1986; 256: 2540-2544